Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2006 June;58(3) > Minerva Ginecologica 2006 June;58(3):209-14

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  CLINICAL ADVANCES IN CONTRACEPTION 

Minerva Ginecologica 2006 June;58(3):209-14

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: Italian

Oral contraceptives and cancer

La Vecchia C.

1 Istituto di Ricerche Farmacologiche Mario Negri, Milano 2 Istituto di Statistica Medica e Biometria Università degli Studi di Milano, Milano


PDF


Oral contraceptives (OC) convey a protection against ovarian, endometrial and perhaps colorectal cancer. However, OC use is associated with excess risk of breast (current or recent use only), cervical and liver cancer. Benefits and risks of OC use on cancer were reviewed in 2005 by a Working Group at the International Agency for Research on Cancer, which concluded that combined OCs are carcinogenic to humans, based on an increased risk for hepatocellular carcinoma, cervical and (for current use only) breast cancers. The Working Group also concluded that there is conclusive evidence that OCs have a protective effect against cancers of the ovary and endometrium.

top of page